Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
FRAG HGH 176-191
HGH Fragment 176–191 is the C-terminal 16-amino-acid segment of human growth hormone. It is studied in lipid-metabolism models and should be kept distinct from full-length HGH and from the modified fragment AOD-9604.
Loading your saved choices…
FRAG HGH 176-191 is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If FRAG HGH 176-191 is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding Frag HGH 176-191
Explore the science, research focus, and key information behind this compound.
What is Frag HGH 176-191?+
This fragment is selected when a study isolates residues 176–191 rather than using full-length HGH.
What Researchers Study+
Researchers examine GH-fragment comparisons, Lipid-metabolism models, and Metabolic signalling.
How Frag HGH 176-191 Works+
Preclinical research proposed that the C-terminal region contributes to some lipid-related effects of growth hormone without recreating the full growth-promoting signal. In plain language, the fragment is a tool for asking whether one small region carries a separable metabolic function.
Research at a Glance+
A C-terminal lipid-related region was proposed. Cell and animal work generated the hypothesis that GH’s C terminus has separable metabolic activity. The evidence does not establish a clinically useful or safe fragment therapy. Frag 176–191 is not AOD-9604. AOD-9604 is a modified analogue based on the region; the unmodified fragment is a different material. Development and assay results should stay attached to the exact sequence. A fragment does not inherit full HGH effects. It should not be marketed with somatropin’s clinical deficiency evidence, growth effects, dosing, or safety profile.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.